Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood - PubMed (original) (raw)
Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood
M Helen Huls et al. J Vis Exp. 2013.
Abstract
The potency of clinical-grade T cells can be improved by combining gene therapy with immunotherapy to engineer a biologic product with the potential for superior (i) recognition of tumor-associated antigens (TAAs), (ii) persistence after infusion, (iii) potential for migration to tumor sites, and (iv) ability to recycle effector functions within the tumor microenvironment. Most approaches to genetic manipulation of T cells engineered for human application have used retrovirus and lentivirus for the stable expression of CAR(1-3). This approach, although compliant with current good manufacturing practice (GMP), can be expensive as it relies on the manufacture and release of clinical-grade recombinant virus from a limited number of production facilities. The electro-transfer of nonviral plasmids is an appealing alternative to transduction since DNA species can be produced to clinical grade at approximately 1/10(th) the cost of recombinant GMP-grade virus. To improve the efficiency of integration we adapted Sleeping Beauty (SB) transposon and transposase for human application(4-8). Our SB system uses two DNA plasmids that consist of a transposon coding for a gene of interest (e.g. 2(nd) generation CD19-specific CAR transgene, designated CD19RCD28) and a transposase (e.g. SB11) which inserts the transgene into TA dinucleotide repeats(9-11). To generate clinically-sufficient numbers of genetically modified T cells we use K562-derived artificial antigen presenting cells (aAPC) (clone #4) modified to express a TAA (e.g. CD19) as well as the T cell costimulatory molecules CD86, CD137L, a membrane-bound version of interleukin (IL)-15 (peptide fused to modified IgG4 Fc region) and CD64 (Fc-γ receptor 1) for the loading of monoclonal antibodies (mAb)(12). In this report, we demonstrate the procedures that can be undertaken in compliance with cGMP to generate CD19-specific CAR(+) T cells suitable for human application. This was achieved by the synchronous electro-transfer of two DNA plasmids, a SB transposon (CD19RCD28) and a SB transposase (SB11) followed by retrieval of stable integrants by the every-7-day additions (stimulation cycle) of γ-irradiated aAPC (clone #4) in the presence of soluble recombinant human IL-2 and IL-21(13). Typically 4 cycles (28 days of continuous culture) are undertaken to generate clinically-appealing numbers of T cells that stably express the CAR. This methodology to manufacturing clinical-grade CD19-specific T cells can be applied to T cells derived from peripheral blood (PB) or umbilical cord blood (UCB). Furthermore, this approach can be harnessed to generate T cells to diverse tumor types by pairing the specificity of the introduced CAR with expression of the TAA, recognized by the CAR, on the aAPC.
Figures
Similar articles
- Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Singh H, et al. PLoS One. 2013 May 31;8(5):e64138. doi: 10.1371/journal.pone.0064138. Print 2013. PLoS One. 2013. PMID: 23741305 Free PMC article. - Sleeping beauty system to redirect T-cell specificity for human applications.
Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Maiti SN, et al. J Immunother. 2013 Feb;36(2):112-23. doi: 10.1097/CJI.0b013e3182811ce9. J Immunother. 2013. PMID: 23377665 Free PMC article. - A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
Singh H, Huls H, Kebriaei P, Cooper LJ. Singh H, et al. Immunol Rev. 2014 Jan;257(1):181-90. doi: 10.1111/imr.12137. Immunol Rev. 2014. PMID: 24329797 Free PMC article. Review. - Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ. Deniger DC, et al. Mol Ther. 2013 Mar;21(3):638-47. doi: 10.1038/mt.2012.267. Epub 2013 Jan 8. Mol Ther. 2013. PMID: 23295945 Free PMC article. - A transposon and transposase system for human application.
Hackett PB, Largaespada DA, Cooper LJ. Hackett PB, et al. Mol Ther. 2010 Apr;18(4):674-83. doi: 10.1038/mt.2010.2. Epub 2010 Jan 26. Mol Ther. 2010. PMID: 20104209 Free PMC article. Review.
Cited by
- Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Singh H, et al. PLoS One. 2013 May 31;8(5):e64138. doi: 10.1371/journal.pone.0064138. Print 2013. PLoS One. 2013. PMID: 23741305 Free PMC article. - Global Manufacturing of CAR T Cell Therapy.
Levine BL, Miskin J, Wonnacott K, Keir C. Levine BL, et al. Mol Ther Methods Clin Dev. 2016 Dec 31;4:92-101. doi: 10.1016/j.omtm.2016.12.006. eCollection 2017 Mar 17. Mol Ther Methods Clin Dev. 2016. PMID: 28344995 Free PMC article. Review. - Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.
Field AC, Vink C, Gabriel R, Al-Subki R, Schmidt M, Goulden N, Stauss H, Thrasher A, Morris E, Qasim W. Field AC, et al. PLoS One. 2013 Jun 28;8(6):e68201. doi: 10.1371/journal.pone.0068201. Print 2013. PLoS One. 2013. PMID: 23840834 Free PMC article. - Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.
Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ. Jena B, et al. PLoS One. 2013;8(3):e57838. doi: 10.1371/journal.pone.0057838. Epub 2013 Mar 1. PLoS One. 2013. PMID: 23469246 Free PMC article. - Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going?
Magnani CF, Tettamanti S, Alberti G, Pisani I, Biondi A, Serafini M, Gaipa G. Magnani CF, et al. Cells. 2020 May 27;9(6):1337. doi: 10.3390/cells9061337. Cells. 2020. PMID: 32471151 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA141303/CA/NCI NIH HHS/United States
- CA16672/CA/NCI NIH HHS/United States
- R33 CA116127/CA/NCI NIH HHS/United States
- R01 CA120956/CA/NCI NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- R01 CA124782/CA/NCI NIH HHS/United States
- CA136411/CA/NCI NIH HHS/United States
- P50 CA136411/CA/NCI NIH HHS/United States
- P01 CA148600/CA/NCI NIH HHS/United States
- R21 CA116127/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials